Qureight’s Vascul8 model has been validated in a peer-reviewed study marking a significant advance in the treatment of ...
Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company’s cardio-pulmonary portfolio and pipeline at the American Heart ...
Study published in ‘American Journal of Respiratory Cell and Molecular Biology’ validates Qureight’s deep-learning models and imaging platform beyond fibrotic lung disease, into new therapeutic areas ...
The first of its kind RCT in acute intermediate-high-risk PE used a surrogate endpoint, but more data are on the horizon.
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of ...
This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA.The STORM-PE randomized controlled trial, presented at TCT ...
Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more here.
San Juan Regional Medical Center has added a PET/CT platform to its nuclear cardiac imaging program, becoming one of only ...
In addition, the doctors of the clinic specialize in the elimination of lesions in the lower limbs. In severe cases of atherosclerosis, blood vessels become clogged with blood clots, blood stops ...
Background Mixed connective tissue disease (MCTD) has long been debated as an early nonspecific phase/symptom of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback